Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis

Antiviral Therapy

Volumn 19, Issue 5, 2014, Pages 527-531

  De Nicola, Stella ^a   Aghemo, Alessio ^a   Campise, Maria Rosaria ^a   D'Ambrosio, Roberta ^a   Rumi, Maria Grazia ^a   Messa, Piergiorgio ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CREATININE; FERROUS SULFATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; DOWN REGULATION; DRUG EFFICACY; ECHOGRAPHY; ELASTOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROANGIOPATHY; NEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; THROMBOEMBOLISM; TREATMENT DURATION; VIRUS LOAD; COMPLICATION; DRUG COMBINATION; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C, CHRONIC; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84924334445     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2684     Document Type: Article

References (18)

1. Cacoub P, Renou C, Rosenthal E., et al Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 2000; 79:47-56.
2. Johnson RJ, Gretch DR, Yamabe H, Hart J., Bacchi CE Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-470.
3. Tarantino A, Campise M, Banfi G., et al Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618-623.
4. Latt N, Alachkar N, Gurakar A. Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol 2012; 8:434-445.
5. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C virus-related glomerulonephritis. Kidney Int 2006; 69:436-439.
6. Fabrizi F, Bruchfeld A, Mangano S., et al Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007; 30:212-219.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
8. Zeuzem S, Andreone P, Pol S., et al Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
9. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
10. Bacon BR, Gordon SC, Lawitz E, et al Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
11. Sherman KE, Flamm SL, Afdhal N.H., et al Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
12. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Dig Liver Dis 2013; 45:1-7.
13. Shu KH, Lan JL, Wu M.J., et al Ultralow-dose alphainterferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77:1894-1896.
14. Sharma RK, Bansal SB, Gupta A, Gulati S., Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20:677-683.
15. Hèzode C., Dorival C, Zoulim F., et al Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French early access program (ANRS CO20-CUPIC) J Hepatol 2012; 56 Suppl 2:S4.
16. Dumortier J, Guillaud O, Gagnieu M.C., et al Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56:146-149.
17. eMedFusion, The University of Liverpool. Hep Drug Interactions. (Accessed 28 June 2012.) Available from http://www.hep-druginteractions.org
18. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2013; 59:46-48.